Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (101-110 of 457) with videos related to

Pageof 46
Sort By:
Diabetes Technology & Therapeutics|April 25, 2012
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 studyJohn B Buse, Yogish C Kudva, Tadej Battelino, et al.
Diabetes Care|January 14, 2025
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose PensAnne M Komé, Mary M Chandran, Shelby S Tungate Lopez, et al.
Diabetes Care|May 22, 2019
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event ReportingTiansheng Wang, Wenchao Lu, Dandan Li, et al.
Small (Weinheim an Der Bergstrasse, Germany)|March 21, 2017
Insulin-Responsive Glucagon Delivery for Prevention of HypoglycemiaJicheng Yu, Yuqi Zhang, Wujin Sun, et al.
Diabetes Care|May 7, 2017
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized TrialWilliam M Steinberg, John B Buse, Marie Louise Muus Ghorbani, et al.
Diabetes Care|December 16, 2017
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 TrialJulio Rosenstock, John B Buse, Rehan Azeem, et al.
Current Medical Research and Opinion|March 10, 2004
Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetesAnne L Peters Harmel, David M Kendall, John B Buse, et al.
Diabetes Care|October 27, 2004
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesJohn B Buse, Robert R Henry, Jenny Han, et al.
Diabetes Care|July 18, 2018
Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. AdultsTiansheng Wang, Jin-Liern Hong, Emily W Gower, et al.
Diabetes Technology & Therapeutics|April 5, 2023
Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTERichard M Bergenstal, Elise Hachmann-Nielsen, Kajsa Kvist, et al.
Pageof 46

Showing results (101-110 of 457) with videos related to

Sort By:
Pageof 46
Diabetes Technology & Therapeutics|April 25, 2012
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 studyJohn B Buse, Yogish C Kudva, Tadej Battelino, et al.
Diabetes Care|January 14, 2025
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose PensAnne M Komé, Mary M Chandran, Shelby S Tungate Lopez, et al.
Diabetes Care|May 22, 2019
Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event ReportingTiansheng Wang, Wenchao Lu, Dandan Li, et al.
Small (Weinheim an Der Bergstrasse, Germany)|March 21, 2017
Insulin-Responsive Glucagon Delivery for Prevention of HypoglycemiaJicheng Yu, Yuqi Zhang, Wujin Sun, et al.
Diabetes Care|May 7, 2017
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized TrialWilliam M Steinberg, John B Buse, Marie Louise Muus Ghorbani, et al.
Diabetes Care|December 16, 2017
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 TrialJulio Rosenstock, John B Buse, Rehan Azeem, et al.
Current Medical Research and Opinion|March 10, 2004
Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetesAnne L Peters Harmel, David M Kendall, John B Buse, et al.
Diabetes Care|October 27, 2004
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesJohn B Buse, Robert R Henry, Jenny Han, et al.
Diabetes Care|July 18, 2018
Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. AdultsTiansheng Wang, Jin-Liern Hong, Emily W Gower, et al.
Diabetes Technology & Therapeutics|April 5, 2023
Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTERichard M Bergenstal, Elise Hachmann-Nielsen, Kajsa Kvist, et al.
Pageof 46